MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment

被引:150
|
作者
Elliott, Julie M. [2 ]
Wahle, Joseph A. [1 ]
Yokoyama, Wayne M. [1 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Biol & Biomed Sci, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2010年 / 207卷 / 10期
基金
美国国家卫生研究院;
关键词
INHIBITORY RECEPTORS; SELF-TOLERANCE; BONE-MARROW; DEVELOPMENTAL PATHWAYS; REJECTION; MICE; MOLECULES; LY49A; RESPONSIVENESS; EDUCATION;
D O I
10.1084/jem.20100986
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In MHC class I-deficient hosts, natural killer (NK) cells are hyporesponsive to cross-linking of activation receptors. Functional competence requires engagement of a self-major histocompatability complex (MHC) class I-specific inhibitory receptor, a process referred to as "licensing." We previously suggested that licensing is developmentally determined in the bone marrow. In this study, we find that unlicensed mature MHC class I-deficient splenic NK cells show gain-of-function and acquire a licensed phenotype after adoptive transfer into wild-type (WT) hosts. Transferred NK cells produce WT levels of interferon-gamma after engagement of multiple activation receptors, and degranulate at levels equivalent to WT NK cells upon coincubation with target cells. Only NK cells expressing an inhibitory Ly49 receptor specific for a cognate host MHC class I molecule show this gain-of-function. Therefore, these findings, which may be relevant to clinical bone marrow transplantation, suggest that neither exposure to MHC class I ligands during NK development in the BM nor endogenous MHC class I expression by NK cells themselves is absolutely required for licensing.
引用
收藏
页码:2073 / 2079
页数:7
相关论文
共 50 条
  • [1] MHC CLASS I-DEFICIENT MICE
    RAULET, DH
    ADVANCES IN IMMUNOLOGY, VOL 55, 1994, 55 : 381 - 421
  • [2] Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice
    Freland, S
    Chambers, BJ
    Andersson, M
    Van Kaer, L
    Ljunggren, HG
    JOURNAL OF IMMUNOLOGY, 1998, 160 (02): : 572 - 579
  • [3] Immunotherapy of MHC class I-deficient tumors
    Reinis, Milan
    FUTURE ONCOLOGY, 2010, 6 (10) : 1577 - 1589
  • [4] ISOLATION OF FUNCTIONAL MHC CLASS I-DEFICIENT ISLET CELLS
    OSORIO, RW
    ASCHER, NL
    JAENISCH, R
    NATUZZI, ES
    FREISE, CE
    ROBERTS, JP
    STOCK, PG
    TRANSPLANTATION PROCEEDINGS, 1993, 25 (01) : 968 - 969
  • [5] Prospects for immunotherapy of MHC class I-deficient tumours
    Bubeník, J
    FOLIA BIOLOGICA, 2003, 49 (03) : 95 - 99
  • [6] Overcoming immunoevasion in MHC class I-deficient cancers
    Danelli, Luca
    NATURE CANCER, 2024, 5 (12) : 1788 - 1788
  • [7] REJECTION OF KIDNEY ALLOGRAFTS BY MHC CLASS I-DEFICIENT MICE
    MANNON, RB
    NATARAJ, C
    KOTZIN, BL
    GRIFFITHS, R
    GEIER, S
    IBRAHIM, S
    SANFILIPPO, FP
    PLATT, JL
    KURLANDER, R
    COFFMAN, TM
    TRANSPLANTATION, 1995, 59 (05) : 746 - 755
  • [8] Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice
    Salcedo, M
    Andersson, M
    Lemieux, S
    Van Kaer, L
    Chambers, BJ
    Ljunggren, HG
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1998, 28 (04) : 1315 - 1321
  • [9] Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I-deficient mice
    Salcedo, M
    Diehl, AD
    OlssonAlheim, MY
    Sundback, J
    VanKaer, L
    Karre, K
    Ljunggren, HG
    JOURNAL OF IMMUNOLOGY, 1997, 158 (07): : 3174 - 3180
  • [10] MHC class I receptors on natural killer cells: on with the old and in with the new
    Khakoo, SI
    Brooks, CR
    CLINICAL SCIENCE, 2003, 105 (02) : 127 - 140